Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.7K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.8K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.8K
Chemical Synapses01:26

Chemical Synapses

11.1K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
11.1K
Chemical Synapses01:26

Chemical Synapses

4.2K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
4.2K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

1.6K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.6K
Muscle Contraction01:10

Muscle Contraction

8.6K
In skeletal muscles, acetylcholine is released by nerve terminals at the motor endplate—the point of synaptic communication between motor neurons and muscle fibers. The binding of acetylcholine to its receptors on the sarcolemma allows entry of sodium ions into the cell and triggers an action potential in the muscle cell. Thus, electrical signals from the brain are transmitted to the muscle. Subsequently, the enzyme acetylcholinesterase breaks down acetylcholine to prevent excessive...
8.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Duke MG Patient Registry III. Comparative Effectiveness of Azathioprine and Mycophenolate Mofetil in Generalized Myasthenia Gravis, a Retrospective Single Center Review.

Muscle & nerve·2026
Same author

A Distinct Immunological Signature in Late-Onset Myasthenia Gravis: Insights from an Exploratory Proteomics Study.

Annals of neurology·2025
Same author

Sensitivity of Repetitive Nerve Stimulation Performed in Early and Later Stages of Myasthenia Gravis.

Muscle & nerve·2025
Same author

COVID-19 Vaccination and Infection in Myasthenia Gravis: A Longitudinal Patient Survey.

Muscle & nerve·2025
Same author

Serum fibrinogen is not elevated in patients with myasthenia gravis.

Scientific reports·2025
Same author

Immune dysregulation in chronic inflammatory demyelinating polyneuropathy.

Journal of neuroimmunology·2024
Same journal

Key Considerations in Telestroke Program Management.

Continuum (Minneapolis, Minn.)·2026
Same journal

Neurology's Action Potential: Delivering on the Promise of Brain Health.

Continuum (Minneapolis, Minn.)·2026
Same journal

Erratum.

Continuum (Minneapolis, Minn.)·2026
Same journal

Management of Large Artery Atherosclerosis.

Continuum (Minneapolis, Minn.)·2026
Same journal

Thrombolysis, Thrombectomy, and Antithrombotic Therapy for Acute Ischemic Stroke.

Continuum (Minneapolis, Minn.)·2026
Same journal

Stroke in Children and Younger Adults.

Continuum (Minneapolis, Minn.)·2026
See all related articles

Related Experiment Video

Updated: Jan 6, 2026

Antigenic Liposomes for Generation of Disease-specific Antibodies
10:31

Antigenic Liposomes for Generation of Disease-specific Antibodies

Published on: October 25, 2018

12.7K

Autoimmune Myasthenia Gravis.

Vern C Juel

    Continuum (Minneapolis, Minn.)
    |October 2, 2025
    PubMed
    Summary
    This summary is machine-generated.

    This review covers autoimmune myasthenia gravis (MG) diagnosis and management. Novel therapies target specific autoimmune attacks, emphasizing prompt diagnosis and tailored treatment for better outcomes.

    More Related Videos

    Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
    10:32

    Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

    Published on: June 5, 2015

    19.2K
    Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
    10:55

    Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

    Published on: October 31, 2025

    636

    Related Experiment Videos

    Last Updated: Jan 6, 2026

    Antigenic Liposomes for Generation of Disease-specific Antibodies
    10:31

    Antigenic Liposomes for Generation of Disease-specific Antibodies

    Published on: October 25, 2018

    12.7K
    Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
    10:32

    Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

    Published on: June 5, 2015

    19.2K
    Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy
    10:55

    Detection of Anti-MDA5 Autoantibodies Using HeLa Cells and Immunocytochemistry with Light Microscopy

    Published on: October 31, 2025

    636

    Area of Science:

    • Neurology
    • Immunology

    Background:

    • Autoimmune myasthenia gravis (MG) is characterized by fluctuating muscle weakness.
    • Disease heterogeneity and specific patient factors influence management strategies.

    Purpose of the Study:

    • To review the diagnosis and management of autoimmune myasthenia gravis (MG).
    • To cover epidemiology, clinical features, pathophysiology, and therapeutic approaches.
    • To highlight recent advances and novel therapies.

    Main Methods:

    • Review of current literature on myasthenia gravis diagnosis and management.
    • Discussion of diagnostic methods including antibody testing and electrodiagnostics.
    • Analysis of therapeutic strategies and emerging treatments.

    Main Results:

    • Diagnosis relies on clinical presentation, antibody testing (acetylcholine receptor or MuSK), and electrodiagnostic studies.
    • Management requires tailored therapy based on individual patient factors and disease characteristics.
    • Novel therapies targeting complement and neonatal Fc receptors show promise.

    Conclusions:

    • Prompt diagnosis and individualized treatment are essential for managing myasthenia gravis.
    • Advances in understanding pathophysiology are driving the development of targeted therapies.
    • Addressing unique considerations in specific patient subgroups (e.g., ocular MG, thymoma) is crucial.